Sildenafil citrate therapy for pulmonary arterial hypertension [12]

New England Journal of Medicine

Volumn 354, Issue 10, 2006, Pages 1091-

  Hoeper, Marius M ^a   Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; SILDENAFIL; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEMODYNAMICS; HUMAN; LETTER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; NOTE; PATHOPHYSIOLOGY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 33644824449     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053442     Document Type: Letter

References (3)

1. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
2. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63.
3. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.